Merck Sharp & Dohme Corp. v. Pharmascience Inc., 2022 FC 417
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Federal Court (Canada) |
| Citation | 2022 FC 417 |
| Date | 11 April 2022 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
8 practice notes
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...the claims, as construed, inventive, to facilitate the obviousness analysis (see also Merck Sharp and Dohme Corp v Pharmascience Inc, 2022 FC 417 [Pharmascience] at para [188] Takeda argues that the inventive concept is the expression of ‘why’ the claimed subject- matter is in......
-
Boehringer Ingelheim (Canada) Ltd. v. Sandoz Canada Inc., 2023 FC 1149
...that the litigation resulting in Justice Furlanetto’s recent trial decision in Merck Sharp & Dohme Corp v Pharmascience Inc, 2022 FC 417 [Sitagliptin] demonstrates the sort of prejudice that can result when the evidence of a patent owner’s invention story is served only af......
-
Form I: Crystal Form Patents In The Federal Court Of Canada ' A Review Of Case Law On Claims Construction And Selection Patents
...Succinate"); Eli Lilly Canada Inc. v. Novopharm Limited, 2009 FC 301 ("Raloxifene"); Merck Sharp & Dohme Corp v. Pharmascience Inc., 2022 FC 417 ("Sitagliptin"); Les Laboratoires Servier v. Apotex Inc., 2019 FC 616 2 GlaxoSmithKline Inc et al. v. Genpharm Inc et al. (2003), 30 CPR (4th) 360......
-
Form II: Anticipation And Obviousness Of Crystal Form Patents In The Federal Court Of Canada
...Desvenlafaxine-Teva supra at para. 39-40; FCA Desvenlafaxine-Apotex supra at para. 39 15. Merck Sharp & Dohme Corp v. Pharmascience Inc., 2022 FC 417 16. Sitagliptin supra at para. 183. 17. Sitagliptin supra at paras. 201-202. 18. Sitagliptin supra at para. 249. 19. Adama Makhteshim Ltd., 2......
Request a trial to view additional results
2 cases
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...the claims, as construed, inventive, to facilitate the obviousness analysis (see also Merck Sharp and Dohme Corp v Pharmascience Inc, 2022 FC 417 [Pharmascience] at para [188] Takeda argues that the inventive concept is the expression of ‘why’ the claimed subject- matter is in......
-
Boehringer Ingelheim (Canada) Ltd. v. Sandoz Canada Inc., 2023 FC 1149
...that the litigation resulting in Justice Furlanetto’s recent trial decision in Merck Sharp & Dohme Corp v Pharmascience Inc, 2022 FC 417 [Sitagliptin] demonstrates the sort of prejudice that can result when the evidence of a patent owner’s invention story is served only af......
6 firm's commentaries
-
Form I: Crystal Form Patents In The Federal Court Of Canada ' A Review Of Case Law On Claims Construction And Selection Patents
...Succinate"); Eli Lilly Canada Inc. v. Novopharm Limited, 2009 FC 301 ("Raloxifene"); Merck Sharp & Dohme Corp v. Pharmascience Inc., 2022 FC 417 ("Sitagliptin"); Les Laboratoires Servier v. Apotex Inc., 2019 FC 616 2 GlaxoSmithKline Inc et al. v. Genpharm Inc et al. (2003), 30 CPR (4th) 360......
-
Form II: Anticipation And Obviousness Of Crystal Form Patents In The Federal Court Of Canada
...Desvenlafaxine-Teva supra at para. 39-40; FCA Desvenlafaxine-Apotex supra at para. 39 15. Merck Sharp & Dohme Corp v. Pharmascience Inc., 2022 FC 417 16. Sitagliptin supra at para. 183. 17. Sitagliptin supra at paras. 201-202. 18. Sitagliptin supra at para. 249. 19. Adama Makhteshim Ltd., 2......
-
Canadian Patent Law: 2022 Year In Review
...argument of invalidity in respect of a patent covering Merck's JANUVIA product was released in Merck Sharp & Dohme v Pharmascinence, (2022 FC 417). The patent at issue claimed, inter alia, an enantiomer of a particular salt and crystalline form of the active ingredient sitagliptin. That thi......
-
Federal Court finds salt patent valid in a PM(NOC) action regarding sitagliptin
...have been sufficient as of the filing date. *** Merck Sharp & Dohme Corp. v Pharmascience Inc., 2022 FC 417 an infringement action concerning sitagliptin phosphate monohydrate products under the Patented Medicines (Notice of Compliance) Regulations (the Regulations). The Court dismissed all......
Request a trial to view additional results